Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

COMy 2021

VJHemOnc is an Official Media Partner for the 7th World Congress on Controversies in Multiple Myeloma (COMy). The leading European meeting in multiple myeloma will cover disease biology, novel therapies & trial updates, treating the young and elderly, smoldering myeloma and amyloidosis.

Recent Updates

View all
4:46
Does ASCT still have a place in myeloma treatment?
Muzaffar Qazilbash • 12 May 2021
3:06
Exciting therapeutic developments on the horizon for WM
Steven Treon • 6 May 2021
5:07
New approaches to the treatment of elderly myeloma
Meral Beksac • 10 May 2021
3:38
CITE-seq analysis predicts response to CAR-T therapy and bispecifics in myeloma
Paola Neri • 19 Apr 2021

Myeloma

View all
2:06
Pembrolizumab for consolidation in myeloma
Enrique Ocio • 16 Apr 2021
3:24
Novel agents for the management of R/R myeloma
Enrique Ocio • 16 Apr 2021

Waldenström’s Macroglobulinemia

View all
4:07
Challenges associated with Waldenström’s
Jorge Castillo • 16 Apr 2021
3:28
Emerging therapies for WM: acalabrutinib and zanubrutinib
Steven Treon • 6 May 2021

CAR-T

View all
2:18
Moving forward: bringing CAR-T therapy to a frontline setting in myeloma
Thomas Martin • 22 Apr 2021
5:33
CARs & MAbs: broadening the myeloma armamentarium
Niels van de Donk • 29 Apr 2021

Disease biology

View all
2:54
Waldenström’s therapy: what’s on the horizon?
Jorge Castillo • 16 Apr 2021
4:07
Challenges associated with Waldenström’s
Jorge Castillo • 16 Apr 2021

Trial Updates

View all
10:16
Melflufen: current trials and future directions
Paul Richardson • 20 Apr 2021
2:48
Dara-Kd shows efficacy in len-refractory cohort in latest CANDOR reports
Saad Usmani • 17 May 2021

Controversies

View all
2:25
Complementary and alternative medicine in hematologic disease: help or harm?
Mohamad Mohty • 16 Apr 2021
2:00
Treating multiple myeloma resistant to BCMA-targeted therapy
Niels van de Donk • 29 Apr 2021
Visit the Multiple Myeloma Channel for the latest updates from leading experts

The content of VJHemOnc is intended for healthcare professionals